Gestalt Diagnostics, Inc. has filed a notice of an exempt offering of securities to raise $9,253,803.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Gestalt Diagnostics, Inc. is raising up to $9,253,803.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Gestalt Diagnostics, Inc.
Gestalt transforms pathology through an intelligent, configurable, and vendor-neutral, AI-driven, digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow solution is a cloud-based digital pathology enterprise platform that can easily be customized based on your specific preferences. This platform consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing their invaluable experience where it matters most.
To learn more about Gestalt Diagnostics, Inc., visit http://www.gestaltdiagnostics.com/
Gestalt Diagnostics, Inc. Linkedin Page: https://www.linkedin.com/company/gestalt-diagnostics/
Contact:
Dan Roark, President and Chief Executive Officer
509-492-4912
https://www.linkedin.com/in/dan-roark-665723/
SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.
